These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 21332711

  • 1. Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome.
    Ghoti H, Fibach E, Westerman M, Gordana O, Ganz T, Rachmilewitz EA.
    Br J Haematol; 2011 Apr; 153(1):118-20. PubMed ID: 21332711
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of deferasirox in myelodysplastic syndromes.
    Breccia M, Alimena G.
    Ann Hematol; 2013 Jul; 92(7):863-70. PubMed ID: 23417759
    [Abstract] [Full Text] [Related]

  • 3. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
    Kikuchi S, Kobune M, Iyama S, Sato T, Murase K, Kawano Y, Takada K, Ono K, Kaneko Y, Miyanishi K, Sato Y, Hayashi T, Takimoto R, Kato J.
    Free Radic Biol Med; 2012 Aug 15; 53(4):643-8. PubMed ID: 22705364
    [Abstract] [Full Text] [Related]

  • 4. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
    Cermak J, Jonasova A, Vondrakova J, Cervinek L, Belohlavkova P, Neuwirtova R.
    Leuk Res; 2013 Dec 15; 37(12):1612-5. PubMed ID: 23937987
    [Abstract] [Full Text] [Related]

  • 5. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S.
    Eur J Haematol; 2014 Jun 15; 92(6):527-36. PubMed ID: 24580147
    [Abstract] [Full Text] [Related]

  • 6. Iron chelation therapy in myelodysplastic syndrome - Cui bono?
    Tefferi A, Stone RM.
    Leukemia; 2009 Aug 15; 23(8):1373. PubMed ID: 19672273
    [No Abstract] [Full Text] [Related]

  • 7. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.
    Ann Hematol; 2013 Jan 15; 92(2):191-8. PubMed ID: 23073603
    [Abstract] [Full Text] [Related]

  • 8. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.
    Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, Schmid M, Taylor K, Vassilieff D, Habr D, Domokos G, Roubert B, Rose C, EPIC study investigators.
    Leuk Res; 2010 Sep 15; 34(9):1143-50. PubMed ID: 20451251
    [Abstract] [Full Text] [Related]

  • 9. Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes.
    Ghoti H, Fibach E, Merkel D, Perez-Avraham G, Grisariu S, Rachmilewitz EA.
    Haematologica; 2010 Aug 15; 95(8):1433-4. PubMed ID: 20421274
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.
    Greenberg PL, Koller CA, Cabantchik ZI, Warsi G, Glynos T, Paley C, Schiffer C.
    Leuk Res; 2010 Dec 15; 34(12):1560-5. PubMed ID: 20615548
    [Abstract] [Full Text] [Related]

  • 13. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
    Maurillo L, Breccia M, Buccisano F, Voso MT, Niscola P, Trapè G, Tatarelli C, D'Addosio A, Latagliata R, Fenu S, Piccioni AL, Fragasso A, Aloe Spiriti MA, Refrigeri M, Criscuolo M, Musto P, Venditti A.
    Eur J Haematol; 2015 Jul 15; 95(1):52-6. PubMed ID: 25764148
    [Abstract] [Full Text] [Related]

  • 14. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.
    Taher AT, Temraz S, Cappellini MD.
    Expert Rev Hematol; 2013 Oct 15; 6(5):495-509. PubMed ID: 24083402
    [Abstract] [Full Text] [Related]

  • 15. Deferasirox (Exjade) for the treatment of iron overload.
    Cappellini MD, Taher A.
    Acta Haematol; 2009 Oct 15; 122(2-3):165-73. PubMed ID: 19907154
    [Abstract] [Full Text] [Related]

  • 16. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.
    Messa E, Cilloni D, Messa F, Arruga F, Roetto A, Saglio G.
    Acta Haematol; 2008 Oct 15; 120(2):70-4. PubMed ID: 18827475
    [Abstract] [Full Text] [Related]

  • 17. Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients.
    Tolley K, Oliver N, Miranda E, Migliaccio-Walle K, Bozkaya D, Li Q.
    J Med Econ; 2010 Oct 15; 13(3):559-70. PubMed ID: 20812793
    [Abstract] [Full Text] [Related]

  • 18. Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
    Lee SE, Yahng SA, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Kim HJ, Cho SG, Kim DW, Min WS, Park CW, Lee JW.
    Acta Haematol; 2013 Oct 15; 129(2):72-7. PubMed ID: 23154600
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes.
    Hartmann J, Braulke F, Sinzig U, Wulf G, Maas JH, Konietschke F, Haase D.
    Leuk Res; 2013 Mar 15; 37(3):327-32. PubMed ID: 23259989
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.